Show simple item record

dc.contributor.authorBoscolo-Rizzo, Paolo
dc.contributor.authorTirelli, Giancarlo
dc.contributor.authorMeloni, Pierluigi
dc.contributor.authorHopkins, Claire
dc.contributor.authorMadeddu, Giordano
dc.contributor.authorDe Vito, Andrea
dc.contributor.authorGardenal, Nicoletta
dc.contributor.authorValentinotti, Romina
dc.contributor.authorTofanelli, Margherita
dc.contributor.authorBorsetto, Daniele
dc.contributor.authorLechien, Jerome R
dc.contributor.authorPolesel, Jerry
dc.contributor.authorDe Riu, Giacomo
dc.contributor.authorVaira, Luigi Angelo
dc.date.accessioned2022-03-31T18:01:40Z
dc.date.available2022-03-31T18:01:40Z
dc.date.issued2022-03-14
dc.date.submitted2022-02-17
dc.identifier.issn2042-6976
dc.identifier.otheralr22995
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/335617
dc.description.abstractBACKGROUND: The aim of this study was to estimate the prevalence of self-reported chemosensory dysfunction in a study cohort of subjects who developed a mild-to-moderate coronavirus disease 2019 (COVID-19) in the period from January 17, 2022, to February 4, 2022 (Omicron proxy period) and compared that with a historical series of patients testing positive for severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection between March and April, 2020 (comparator period). METHODS: Prospective study based on the 22-item Sino-Nasal Outcome Tool (SNOT-22), item "sense of smell or taste" and additional outcomes. RESULTS: Patients' characteristics and clinical presentations of COVID-19 were evaluated and compared in 779 patients, 338 of the study cohort and 441 of the historical series. The prevalence of self-reported chemosensory dysfunction during the proxy Omicron period (32.5%; 95% confidence interval [CI], 27.6-37.8) was significantly lower from that during the comparator period (66.9%; 95% CI, 62.3-71.3) (p < 0.001). Nearly one-quarter of patients (24.6%; 95% CI, 20.1-29.5) reported an altered sense of smell during the proxy Omicron period compared to 62.6% (95% CI, 57.9-67.1) during the comparator period (p < 0.001). Similarly, the prevalence of an altered sense of taste dropped to 26.9% (95% CI, 22.3-32.0) during the proxy Omicron period from 57.4% (95% CI, 52.6-62.0) during the comparator period (p < 0.001). The severity of chemosensory dysfunction was lower in the proxy Omicron period compared to the comparator period (p < 0.001). CONCLUSION: The prevalence and the severity of COVID-19-associated smell and taste dysfunction has dropped significantly with the advent of the Omicron variant but it still remains above 30%.
dc.languageen
dc.publisherWiley
dc.subjectORIGINAL ARTICLE
dc.subjectORIGINAL ARTICLES
dc.subjectCOVID‐19
dc.subjectolfactory dysfunction
dc.subjectOmicron variant
dc.subjectSARS‐CoV‐2
dc.subjectsmell
dc.subjecttaste
dc.titleCoronavirus disease 2019 (COVID-19)-related smell and taste impairment with widespread diffusion of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) Omicron variant.
dc.typeArticle
dc.date.updated2022-03-31T18:01:40Z
prism.publicationNameInt Forum Allergy Rhinol
dc.identifier.doi10.17863/CAM.83048
dcterms.dateAccepted2022-03-08
rioxxterms.versionofrecord10.1002/alr.22995
rioxxterms.versionAO
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.identifier.eissn2042-6984
cam.issuedOnline2022-03-24


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record